HCM
DMAA

Highbridge Capital Management’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Highbridge Capital Management’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.9M Buy
+1,323,351
New +$13.8M 0.45% 47

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
MSU
Mizuho Securities USA New York $6.2B AUM 35.46% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

Highbridge Capital Management's DMAA Position: Q1 2026 in Review

Highbridge Capital Management opened a new position in Drugs Made In America Acquisition Corp (DMAA) in Q1 2026: 1,323,351 shares worth $13.9M. The stake represents 0.45% of the portfolio and ranks #47 among its holdings.

39 funds tracked by Wall St. Rank hold DMAA as of Q1 2026.

  • Highbridge Capital Management held 1,323,351 shares of Drugs Made In America Acquisition Corp worth $13.9M as of Q1 2026.
  • Drugs Made In America Acquisition Corp was a new Highbridge Capital Management position in Q1 2026.
  • Drugs Made In America Acquisition Corp made up 0.45% of Highbridge Capital Management's portfolio in Q1 2026, its #47 holding.
  • 39 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q1 2026.

Based on Highbridge Capital Management's 13F filing for Q1 2026, filed 15 May 2026.